Abbott Laboratories News
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
see moreAbbott Laboratories Market News
6d
Abbott Laboratories' Q2 2026 Earnings Exceed Expectations, Stock Responds Positively
- Abbott Laboratories reports strong Q2 2026 earnings, boosting stock performance.
10d
Abbott Laboratories' Q2 2026 Earnings Beat Expectations, Stock Surges
Abbott Laboratories reports strong Q2 2026 earnings, boosting stock price.
17d
Abbott Laboratories' Q2 2026 Performance and Strategic Developments
Abbott's Q2 2026 results showcase strong growth and strategic advancements.
24d
Abbott Laboratories' Q1 2026 Performance and Strategic Moves Amid Market Challenges
Abbott's Q1 2026 results and strategic initiatives amid market challenges.
29d
Abbott Laboratories' Strategic Moves and Financial Performance in 2026
Abbott's 2026 financials and strategic acquisitions bolster its market position.
11 May at 03:58
Abbott Advances: Ultreon 3.0 Approval Boosts ABT!!
Abbott secured FDA and CE clearance for its Ultreon 3.0 AI OCT platform and reported solid Q1 2026 results—moves that strengthen its medical devices franchise while management updates guidance and adds strategic capital flexibility.
04 May at 03:57
Abbott Slides to 52‑Week Low; Ultreon 3.0 Cleared
Abbott (ABT) hit a 52-week low amid heavy selling and a post-earnings pullback, even as the company secured FDA clearance for Ultreon 3.0 and reported solid Q1 results with slightly lowered guidance driven by acquisition-related dilution.